ATE129644T1 - System zur verabreichung von einem, eine übung simulierenden medikaments im geschlossenen kreislauf. - Google Patents

System zur verabreichung von einem, eine übung simulierenden medikaments im geschlossenen kreislauf.

Info

Publication number
ATE129644T1
ATE129644T1 AT89301553T AT89301553T ATE129644T1 AT E129644 T1 ATE129644 T1 AT E129644T1 AT 89301553 T AT89301553 T AT 89301553T AT 89301553 T AT89301553 T AT 89301553T AT E129644 T1 ATE129644 T1 AT E129644T1
Authority
AT
Austria
Prior art keywords
responses
adaptive
exercise
cad
acute
Prior art date
Application number
AT89301553T
Other languages
English (en)
Inventor
Ronald Ralph Tuttle
Iii Clinton Eugene Browne
Original Assignee
Gensia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia Inc filed Critical Gensia Inc
Application granted granted Critical
Publication of ATE129644T1 publication Critical patent/ATE129644T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C07C45/305—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation with halogenochromate reagents, e.g. pyridinium chlorochromate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00—Surgery
    • Y10S128/13—Infusion monitoring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT89301553T 1988-02-19 1989-02-17 System zur verabreichung von einem, eine übung simulierenden medikaments im geschlossenen kreislauf. ATE129644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15787588A 1988-02-19 1988-02-19
US07/308,683 US5108363A (en) 1988-02-19 1989-02-09 Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist

Publications (1)

Publication Number Publication Date
ATE129644T1 true ATE129644T1 (de) 1995-11-15

Family

ID=26854551

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95101920T ATE159710T1 (de) 1988-02-19 1989-02-17 Die diagnose, die bewertung und die behandlung von einer krankheit der kranzarterie durch die übungssimulierung unter verwendung von einer geschlossenen kreislauf arzneimittellieferung eines übungssimulierenden beta-agonisten
AT89301553T ATE129644T1 (de) 1988-02-19 1989-02-17 System zur verabreichung von einem, eine übung simulierenden medikaments im geschlossenen kreislauf.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95101920T ATE159710T1 (de) 1988-02-19 1989-02-17 Die diagnose, die bewertung und die behandlung von einer krankheit der kranzarterie durch die übungssimulierung unter verwendung von einer geschlossenen kreislauf arzneimittellieferung eines übungssimulierenden beta-agonisten

Country Status (13)

Country Link
US (4) US5108363A (de)
EP (2) EP0329464B1 (de)
JP (2) JP2806543B2 (de)
AT (2) ATE159710T1 (de)
AU (1) AU634152B2 (de)
DE (2) DE68928422T2 (de)
DK (1) DK73589A (de)
ES (2) ES2081299T3 (de)
FI (1) FI890776A7 (de)
GR (2) GR3018764T3 (de)
IE (2) IE80716B1 (de)
NO (1) NO890704L (de)
NZ (1) NZ239270A (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6144385A (ja) * 1984-08-07 1986-03-04 Tokyu Constr Co Ltd 構造物内の放射線吸収体の探査方法
IL82997A0 (en) * 1986-07-11 1987-12-20 Tanabe Seiyaku Co Method for epimerizing an optically active benzyl alcohol derivative
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
TW209832B (de) * 1989-10-10 1993-07-21 Glaxo Group Ltd
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5556415A (en) * 1990-01-29 1996-09-17 Mcewen; James A. Physiologic tourniquet for intravenous regional anesthesia
US5607447A (en) * 1993-09-28 1997-03-04 Mcewen; James A. Physiologic tourniquet
US5254087A (en) * 1990-01-29 1993-10-19 Ivra Systems, Inc. Tourniquet apparatus for intravenous regional anesthesia
US5281623A (en) * 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
WO1993009779A1 (en) * 1991-11-13 1993-05-27 Gensia, Inc. Methods for increasing the sensitivity and decreasing the side effects of pharmacological stress testing for coronary artery disease
IL104365A0 (en) * 1992-01-31 1993-05-13 Gensia Pharma Method and apparatus for closed loop drug delivery
HUT64459A (en) * 1992-03-31 1994-01-28 Richter Gedeon Vegyeszet Process and apparatus for the diagnostics of cardiovascular
US5752521A (en) 1993-11-12 1998-05-19 Dardik; Irving I. Therapeutic exercise program
US6397098B1 (en) * 1994-09-21 2002-05-28 Medrad, Inc. Data communication and control for medical imaging systems
US5840026A (en) * 1994-09-21 1998-11-24 Medrad, Inc. Patient specific dosing contrast delivery systems and methods
US5551953A (en) * 1994-10-31 1996-09-03 Alza Corporation Electrotransport system with remote telemetry link
US7204848B1 (en) 1995-03-01 2007-04-17 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
US5775329A (en) * 1995-06-07 1998-07-07 Gensia, Inc. Method and compounds for diagnosing coronary artery disease
US5931853A (en) * 1995-08-25 1999-08-03 Mcewen; James A. Physiologic tourniquet with safety circuit
US5855589A (en) * 1995-08-25 1999-01-05 Mcewen; James A. Physiologic tourniquet for intravenous regional anesthesia
US6430997B1 (en) * 1995-11-06 2002-08-13 Trazer Technologies, Inc. System and method for tracking and assessing movement skills in multidimensional space
DE69614146T2 (de) * 1995-12-22 2002-04-11 Abbott Laboratories, Abbott Park Verfahren zur herstellung von alkyl oder aryl aldehydzwischenprodukten
US5874601A (en) * 1996-03-14 1999-02-23 Abbott Laboratories Process of protecting a 1,2-aminoalcohol for reductive amination coupling
US5706822A (en) * 1996-03-29 1998-01-13 Kozz Incorporated Method and computer program for creating individualized exercise protocols
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5713923A (en) * 1996-05-13 1998-02-03 Medtronic, Inc. Techniques for treating epilepsy by brain stimulation and drug infusion
AU4967997A (en) * 1996-12-02 1998-06-29 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
US6018679A (en) * 1997-01-29 2000-01-25 Novartis Finance Corp. Iontophoretic transdermal delivery and control of adverse side-effects
CA2334408C (en) 1998-06-03 2007-03-27 Scott Laboratories, Inc. Apparatus and method for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures
JP2002520101A (ja) * 1998-07-13 2002-07-09 ジェネトロニクス、インコーポレーテッド 電気的に補助される化粧用薬剤の局部送達法および装置
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US6361522B1 (en) * 1999-10-21 2002-03-26 Cardiac Pacemakers, Inc. Drug delivery system for implantable cardiac device
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
US9741001B2 (en) 2000-05-18 2017-08-22 Carefusion 303, Inc. Predictive medication safety
US9069887B2 (en) * 2000-05-18 2015-06-30 Carefusion 303, Inc. Patient-specific medication management system
EP1316048A2 (de) 2000-05-18 2003-06-04 ALARIS Medical Systems, Inc. Entfernter abgabegegenstand und arzneimittelabgabeverwaltungssystem
US9427520B2 (en) 2005-02-11 2016-08-30 Carefusion 303, Inc. Management of pending medication orders
US11087873B2 (en) 2000-05-18 2021-08-10 Carefusion 303, Inc. Context-aware healthcare notification system
US10353856B2 (en) 2011-03-17 2019-07-16 Carefusion 303, Inc. Scalable communication system
US10062457B2 (en) 2012-07-26 2018-08-28 Carefusion 303, Inc. Predictive notifications for adverse patient events
AU7148001A (en) 2000-06-30 2002-01-14 Lifewaves International Inc Systems and methods for assessing and modifying an individual's physiological condition
US7369890B2 (en) 2000-11-02 2008-05-06 Cardiac Pacemakers, Inc. Technique for discriminating between coordinated and uncoordinated cardiac rhythms
US6689117B2 (en) 2000-12-18 2004-02-10 Cardiac Pacemakers, Inc. Drug delivery system for implantable medical device
US7493162B2 (en) * 2001-06-15 2009-02-17 Cardiac Pacemakers, Inc. Pulmonary vein stent for treating atrial fibrillation
US7209783B2 (en) * 2001-06-15 2007-04-24 Cardiac Pacemakers, Inc. Ablation stent for treating atrial fibrillation
US7340303B2 (en) 2001-09-25 2008-03-04 Cardiac Pacemakers, Inc. Evoked response sensing for ischemia detection
CA2465625C (en) * 2001-11-01 2007-07-10 Scott Laboratories, Inc. User interface for sedation and analgesia delivery systems and methods
US10173008B2 (en) 2002-01-29 2019-01-08 Baxter International Inc. System and method for communicating with a dialysis machine through a network
US20030140928A1 (en) * 2002-01-29 2003-07-31 Tuan Bui Medical treatment verification system and method
US8775196B2 (en) 2002-01-29 2014-07-08 Baxter International Inc. System and method for notification and escalation of medical data
US7236821B2 (en) * 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
US20040176667A1 (en) * 2002-04-30 2004-09-09 Mihai Dan M. Method and system for medical device connectivity
US20040172300A1 (en) * 2002-04-30 2004-09-02 Mihai Dan M. Method and system for integrating data flows
US20040167804A1 (en) * 2002-04-30 2004-08-26 Simpson Thomas L.C. Medical data communication notification and messaging system and method
US20040172301A1 (en) * 2002-04-30 2004-09-02 Mihai Dan M. Remote multi-purpose user interface for a healthcare system
US20050065817A1 (en) * 2002-04-30 2005-03-24 Mihai Dan M. Separation of validated information and functions in a healthcare system
US8234128B2 (en) 2002-04-30 2012-07-31 Baxter International, Inc. System and method for verifying medical device operational parameters
CA2490636A1 (en) * 2002-06-20 2003-12-31 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
US7089055B2 (en) * 2002-06-28 2006-08-08 Cardiac Pacemakers, Inc. Method and apparatus for delivering pre-shock defibrillation therapy
CA2507488A1 (en) * 2002-10-03 2004-04-15 Scott Laboratories, Inc. Systems and methods for providing trend analysis in a sedation and analgesia system
WO2004032051A2 (en) 2002-10-03 2004-04-15 Scott Laboratories, Inc. Systems and methods for providing sensor fusion
US7072711B2 (en) 2002-11-12 2006-07-04 Cardiac Pacemakers, Inc. Implantable device for delivering cardiac drug therapy
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7567841B2 (en) 2004-08-20 2009-07-28 Cardiac Pacemakers, Inc. Method and apparatus for delivering combined electrical and drug therapies
JP2008520287A (ja) 2004-11-16 2008-06-19 メドラッド インコーポレーテッド 薬剤注入に対する患者搬送関数を決定し、患者反応をモデル化するシステム及び方法
US7925330B2 (en) * 2004-11-24 2011-04-12 Medrad, Inc. Devices, systems and methods for determining parameters of one or more phases of an injection procedure
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US8182443B1 (en) * 2006-01-17 2012-05-22 Masimo Corporation Drug administration controller
JP2009531280A (ja) * 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
HUE040477T2 (hu) 2006-12-29 2019-03-28 Bayer Healthcare Llc Betegalapú paramétergeneráló rendszerek gyógyászati injekciós eljárásokhoz
ES2753850T3 (es) * 2007-01-29 2020-04-14 Nat Res Council Canada Uso de catecolaminas y compuestos relacionados como agentes antiangiogénicos
EP2170165B1 (de) 2007-07-17 2018-12-05 Bayer Healthcare LLC Systeme zur bestimmung von parametern für ein verfahren zur schätzung der kardiopulmonalen funktion und zur flüssigkeitsabgabe
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
US10089443B2 (en) 2012-05-15 2018-10-02 Baxter International Inc. Home medical device systems and methods for therapy prescription and tracking, servicing and inventory
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
US8554579B2 (en) 2008-10-13 2013-10-08 Fht, Inc. Management, reporting and benchmarking of medication preparation
US9421330B2 (en) * 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
EP2724739B1 (de) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Tragbares Infusionspumpensystem
US20110137297A1 (en) * 2009-09-17 2011-06-09 Kiani Massi Joe E Pharmacological management system
US9959389B2 (en) 2010-06-24 2018-05-01 Bayer Healthcare Llc Modeling of pharmaceutical propagation and parameter generation for injection protocols
CN104428660A (zh) 2012-05-14 2015-03-18 拜耳医疗保健公司 用于基于x射线管电压确定药用流体注射协议的系统和方法
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8761717B1 (en) 2012-08-07 2014-06-24 Brian K. Buchheit Safety feature to disable an electronic device when a wireless implantable medical device (IMD) is proximate
KR20150048816A (ko) 2012-08-31 2015-05-07 백스터 코포레이션 잉글우드 약제 요청서 집행 시스템 및 방법
KR102078768B1 (ko) 2012-10-26 2020-02-19 백스터 코포레이션 잉글우드 의료 투여분 조제 시스템을 위한 개선된 이미지 취득
EP3453377A1 (de) 2012-10-26 2019-03-13 Baxter Corporation Englewood Verbesserte arbeitsstation für medizinische dosiszubereitung
US11182728B2 (en) 2013-01-30 2021-11-23 Carefusion 303, Inc. Medication workflow management
US10430554B2 (en) 2013-05-23 2019-10-01 Carefusion 303, Inc. Medication preparation queue
US9946844B2 (en) * 2013-02-22 2018-04-17 Cloud Dx, Inc. Systems and methods for monitoring patient medication adherence
JP6660288B2 (ja) 2013-03-13 2020-03-11 ケアフュージョン ３０３、インコーポレイテッド 患者固有投薬管理システム
CN105074766A (zh) 2013-03-13 2015-11-18 康尔福盛303公司 预测性用药安全
US9555379B2 (en) 2013-03-13 2017-01-31 Bayer Healthcare Llc Fluid path set with turbulent mixing chamber, backflow compensator
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
EP3000094A4 (de) 2013-05-22 2017-02-01 Carefusion 303 Inc. Medizinische arbeitsflussverwaltung
EP3161778A4 (de) 2014-06-30 2018-03-14 Baxter Corporation Englewood Verwalteter austausch medizinischer informationen
US11575673B2 (en) 2014-09-30 2023-02-07 Baxter Corporation Englewood Central user management in a distributed healthcare information management system
US11107574B2 (en) 2014-09-30 2021-08-31 Baxter Corporation Englewood Management of medication preparation with formulary management
US12412644B2 (en) 2014-10-24 2025-09-09 Baxter Corporation Englewood Automated exchange of healthcare information for fulfillment of medication doses
EP3937116A1 (de) 2014-12-05 2022-01-12 Baxter Corporation Englewood Datenanalyse für dosiszubereitung
AU2016226164A1 (en) 2015-03-03 2017-10-19 Baxter Corporation Englewood Pharmacy workflow management with integrated alerts
ES2987653T3 (es) 2015-06-25 2024-11-15 Gambro Lundia Ab Sistema y método de dispositivo médico que tiene una base de datos distribuida
EP3423130B1 (de) 2016-03-03 2025-05-14 Bayer Healthcare LLC System und verfahren zur verbesserten fluidabgabe in injektorsystem für mehrere fluide
JP7191821B2 (ja) 2016-11-14 2022-12-19 バイエル・ヘルスケア・エルエルシー 医用流体送出に使用されるシリンジの内容物を確認するための方法およびシステム
AU2017381172A1 (en) 2016-12-21 2019-06-13 Gambro Lundia Ab Medical device system including information technology infrastructure having secure cluster domain supporting external domain
CA3066780A1 (en) 2017-08-31 2019-03-07 Bayer Healthcare Llc Fluid injector system volume compensation system and method
AU2018326485B2 (en) 2017-08-31 2024-01-04 Bayer Healthcare Llc Injector pressure calibration system and method
US11786652B2 (en) 2017-08-31 2023-10-17 Bayer Healthcare Llc System and method for drive member position and fluid injector system mechanical calibration
AU2018323442B2 (en) 2017-08-31 2024-06-27 Bayer Healthcare Llc Fluid path impedance assessment for improving fluid delivery performance
CN110869071B (zh) 2017-08-31 2023-05-02 拜耳医药保健有限公司 流体注入器系统中的动态压力控制的方法
WO2019204605A1 (en) 2018-04-19 2019-10-24 Bayer Healthcare Llc System and method for air detection in fluid injector
CA3111209A1 (en) 2018-08-28 2020-03-05 Bayer Healthcare Llc Fluid injector system with improved ratio performance
JP7450608B2 (ja) 2018-08-28 2024-03-15 バイエル・ヘルスケア・エルエルシー 流体注入器システム、流体の逆流を防止する方法、およびコンピュータプログラム製品
US12138425B2 (en) 2019-05-21 2024-11-12 Tandem Diabetes Care, Inc. System and method for incorporating exercise into closed-loop diabetes therapy
US11969576B2 (en) 2019-07-03 2024-04-30 Tandem Diabetes Care, Inc. Methods of incorporating CGM data into diabetes therapy
US11654236B2 (en) 2019-11-22 2023-05-23 Tandem Diabetes Care, Inc. Systems and methods for automated insulin delivery for diabetes therapy
US11911595B2 (en) 2020-05-18 2024-02-27 Tandem Diabetes Care, Inc. Systems and methods for automated insulin delivery response to meal announcements

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA570892A (en) * 1959-02-17 D. Moed Hendrik Method of producing substituted aralkyl-, phenyl-, alkylamines
DE1144291B (de) * 1957-11-05 1963-02-28 Philips Nv Verfahren zur Herstellung einer optisch-aktiven broncholytisch wirksamen Verbindung
US3135797A (en) * 1958-04-15 1964-06-02 Colgate Palmolive Co Aromatic amino antispasmodic compounds
US3319623A (en) * 1964-07-13 1967-05-16 Seymour B London Blood pressure monitors
FR1541394A (fr) 1966-10-18 1968-10-04 Boehringer Sohn Ingelheim Procédé de fabrication de nouvelles 3, 4-dihydroxyphénylalcanolamines
US3969410A (en) * 1972-01-12 1976-07-13 Boehringer Ingelheim Gmbh 1-(2'-Alkyl-3',4'-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanols-(1) and salts thereof
US3803320A (en) * 1968-07-24 1974-04-09 Geigy Chem Corp Control of insects,acarinae and nematodes with basically substituted 1-cyano-o-carbamoyl-formoximes
US3803230A (en) * 1969-05-30 1974-04-09 Allen & Hanburys Ltd 5-(2-((1-methyl-3-phenylpropyl)amino)ethyl)salicylamide hydrochloride
US3651806A (en) * 1969-10-24 1972-03-28 Philip I Hirshberg Method and apparatus for administering digitalizing medications
GB1301134A (en) * 1970-07-18 1972-12-29 Pfizer Ltd SUBSTITUTED 1-PHENYL-2-ALLYLAMINO-ALKANOLS, 1-PHENYL-2-ALLYLAMINO-ALKANES AND alpha-AMINOALKYLPHENYL KETONES
US4086272A (en) * 1970-07-18 1978-04-25 Pfizer Inc. Phenyl-alkanolamine, alkylamine and alpha-aminoalkyl ketone derivatives as heart stimulants
NL7112938A (de) * 1970-09-30 1972-04-05
US3987200A (en) * 1972-04-12 1976-10-19 Eli Lilly And Company Method for increasing cardiac contractility
JPS5310582B2 (de) * 1973-04-28 1978-04-14
FR2328456A1 (fr) * 1975-10-22 1977-05-20 Bruneau & Cie Lab Derives de phenylethanolamine, leur preparation et leur application en therapeutique
US4080966A (en) * 1976-08-12 1978-03-28 Trustees Of The University Of Pennsylvania Automated infusion apparatus for blood pressure control and method
US4078562A (en) * 1976-08-16 1978-03-14 Diana W. Friedman Infusion pump with feedback control
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
SE402569B (sv) * 1976-11-09 1978-07-10 Aga Ab Anordning vid en andningsapparat for dykare
FI791727A7 (fi) * 1978-06-05 1981-01-01 Ciba Geigy Ag Menetelmä N-alkyloitujen aminoalkoholien valmistamiseksi.
EP0006735B1 (de) * 1978-06-28 1983-06-15 Beecham Group Plc Sekundäre Amine, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung
CA1145766A (en) * 1978-07-03 1983-05-03 Jack Mills Optically active phenethanolamines and method for increasing cardiac contractility
US4845127A (en) * 1978-07-03 1989-07-04 Eli Lilly And Company Phenethanolamines, compositions containing the same and method for effecting weight control
DE3061205D1 (en) * 1979-06-16 1983-01-05 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
US4280494A (en) * 1979-06-26 1981-07-28 Cosgrove Robert J Jun System for automatic feedback-controlled administration of drugs
US4392849A (en) * 1981-07-27 1983-07-12 The Cleveland Clinic Foundation Infusion pump controller
IE56843B1 (en) * 1983-01-31 1992-01-01 Lilly Co Eli Phenethanolamine derivatives in weight control in animals
US4837305A (en) * 1983-02-03 1989-06-06 The Regents Of The University Of California Derivatives of β-adrenergic antagonists
US5135479A (en) * 1983-08-18 1992-08-04 Drug Delivery Systems, Inc. Programmable control and mounting system for transdermal drug applicator
EP0135905A3 (de) * 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane
US4562206A (en) * 1983-12-23 1985-12-31 Key Pharmaceuticals, Inc. Orally effective inotropic compounds
US4828545A (en) * 1984-02-08 1989-05-09 Omni-Flow, Inc. Pressure responsive multiple input infusion system
CA1254091A (en) * 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US5088981A (en) * 1985-01-18 1992-02-18 Howson David C Safety enhanced device and method for effecting application of a therapeutic agent
EP0225872B1 (de) * 1985-06-10 1992-09-02 Drug Delivery Systems Inc. Programmierbare kontrolle und bausystem eines verabreichungsgerätes für transdermische arzneien
US4688577A (en) * 1986-02-10 1987-08-25 Bro William J Apparatus for and method of monitoring and controlling body-function parameters during intracranial observation
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
US4931046A (en) * 1987-05-15 1990-06-05 Newman Martin H Iontophoresis drug delivery system
EP0313638A4 (de) * 1987-05-15 1989-06-14 Martin H Newman Arzneimittelverabreichungssystem durch inophorese.
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US4846792A (en) * 1988-03-08 1989-07-11 Baxter International Inc. Automatic infiltration detection system and method

Also Published As

Publication number Publication date
EP0329464A3 (de) 1991-07-17
JPH0217048A (ja) 1990-01-22
DE68924661T2 (de) 1996-03-21
US5395970A (en) 1995-03-07
AU3008889A (en) 1989-08-24
IE71651B1 (en) 1997-02-26
JPH10276991A (ja) 1998-10-20
AU634152B2 (en) 1993-02-18
DK73589A (da) 1989-08-20
IE80716B1 (en) 1998-12-30
IE960742L (en) 1989-08-19
DK73589D0 (da) 1989-02-17
ATE159710T1 (de) 1997-11-15
US5286252A (en) 1994-02-15
NO890704D0 (no) 1989-02-20
US5460605A (en) 1995-10-24
FI890776A7 (fi) 1989-08-20
DE68924661D1 (de) 1995-12-07
EP0329464A2 (de) 1989-08-23
IE890526L (en) 1989-08-19
ES2111973T3 (es) 1998-03-16
NZ239270A (en) 1993-10-26
US5108363A (en) 1992-04-28
EP0658538B1 (de) 1997-10-29
GR3025892T3 (en) 1998-04-30
FI890776A0 (fi) 1989-02-17
EP0329464B1 (de) 1995-11-02
JP2806543B2 (ja) 1998-09-30
DE68928422T2 (de) 1998-02-26
ES2081299T3 (es) 1996-03-01
DE68928422D1 (de) 1997-12-04
NO890704L (no) 1989-08-21
GR3018764T3 (en) 1996-04-30
EP0658538A1 (de) 1995-06-21

Similar Documents

Publication Publication Date Title
ATE129644T1 (de) System zur verabreichung von einem, eine übung simulierenden medikaments im geschlossenen kreislauf.
Grandin Thinking in pictures, expanded edition: My life with autism
Faaborg-Andersen et al. Action potentials from internal laryngeal muscles during phonation
DE3887152D1 (de) Vorrichtung zum Testen oder Trainieren der unteren Rumpfmuskeln des menschlichen Körpers.
EP0721783A4 (de) Vorbeugungs- und heilmittel für erkrankungen, die durch fibrin- oder thrombusbildung hervorgerufen werden, und ein tiermodell für diese erkrankungen
Johnson A study of emotion revealed in two types of athletic sports contests
Carlisle et al. The X-organ of Crustacea
Bohdanecka et al. Amnesic effects of small bilateral brain puncture in the mouse
Nash The effects of warm-up activities on small group divergent problem-solving with young children
Kellogg et al. " Ambiguous conditioning," a phenomenon of bilateral transfer.
Clark et al. A form of congenital myotonia in goats
JPS51118841A (en) A drug for improving and treating clouding of consciousness
Lynch et al. Within-session data.
RU96107303A (ru) Способ оценки адекватности лечения
DE3765916D1 (de) Sonde zur einfuehrung in den verdauungs- oder ausscheidungstrakt des menschlichen oder tierischen koerpers, insbesondere lithotriptor-sonde.
Gomes Effects of continuous and intermittent training on body composition and selected physiological parameters
Wray Jr et al. Effect of continuous load on the mechanical properties of tendon adhesions
Bean-Bayog et al. Special report: AMSAODD: Plan for certification of members, 1985–1986.
Cole et al. Tests used in the localization of cerebral function in trained monkeys
Conyne et al. A HIM-G interaction process analysis study of facilitator-and self-directed groups
Sanz Ruiz et al. Interactive effect of self-efficacy and incentive value on peripheral physiological reactivity in the performance of a cognitive task.
Repo The holistic approach to rehabilitation: a commentary
Soltysik et al. A further study on the effect of medial prefrontal ablation upon classical defensive conditioned reflexes in dogs
DE69013139D1 (de) Mittel zur Vorbeugung, Diagnose und Therapie von rheumatischen, autoimmunen, Haut- und Bindegewebekrankheiten von unbekannter Aetiologie und Verfahren zu seiner Herstellung und Verwendung.
Parakh et al. Difficult decisions: Animal rights

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee